CD69 and neoplasm: As a whole, we can see a complete activation of the RevCAR T-cells upon the combinatorial targeting of PSCA and PD-L1, not only in terms of T-cell activation (CD69 expression) and tumor cell killing but also in the secretion of pro-inflammatory cytokines and T-cell differentiation, portraying an AND-gated tumor targeting using the RevCAR system.